Nutriband Inc. Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference, scheduled for December 3 at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida. The presentation provides an important platform for the company to showcase its technology platform and business strategy to the investment community. Investors and conference guests may attend at a discounted rate using code NTRBNOBLECON, while those unable to attend in person can access a high-definition webcast the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days.
The company's primary focus involves developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch incorporating proprietary AVERSA technology. This technology represents a significant advancement in transdermal drug delivery systems, specifically designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The full press release detailing the announcement can be viewed at https://nnw.fm/Bx5x3.
AVERSA technology's broad application potential across multiple pharmaceutical products carrying abuse risks makes it particularly relevant given the ongoing opioid abuse crisis affecting public health in the United States and globally. The technology can be incorporated into any transdermal patch, offering versatile solutions for medications with abuse potential. Investors following Nutriband can access the latest news and updates relating to NTRB in the company's newsroom at https://nnw.fm/NTRB.
Emerging growth equity conferences like NobleCon21 serve as critical venues for companies to communicate their value proposition and growth potential directly to potential investors and financial analysts. The timing of this presentation is significant as it allows Nutriband to demonstrate how its AVERSA technology addresses a pressing public health concern while positioning the company for future growth in the pharmaceutical sector. The company maintains its corporate website at www.nutriband.com, though the company notes that any material contained in or derived from its websites is not part of the official press release.
